Hospitalization Patterns and Impact of a Magnetically-Levitated Left Ventricular Assist Device in the MOMENTUM 3 Trial.

Authors:

Himabindu Vidula Koji Takeda Jerry D Estep Scott C Silvestry Carmelo Milano Joseph C Cleveland Daniel J Goldstein Nir Uriel Robert L Kormos Nicholas Dirckx Mandeep R Mehra

JACC Heart Fail 2022 Jul 8;10(7):470-481. Epub 2022 Jun 8.

Center for Advanced Heart Disease, Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, Massachusetts, USA. Electronic address:

Background: In the MOMENTUM 3 (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3) pivotal trial, the HeartMate 3 (HM3) fully magnetically levitated left ventricular assist device (LVAD) demonstrated superiority over the axial-flow HeartMate II (HMII) LVAD. The patterns and predictors of hospitalizations with the HM3 LVAD have not been characterized.

Objectives: This study sought to determine causes, predictors, and impact of hospitalizations during LVAD support.

Methods: Patients discharged after LVAD implantation were analyzed. In the pivotal trial, 485 recipients of HM3 were compared with 471 recipients of HMII. The pivotal trial HM3 group was also compared to 949 recipients of HM3 in the postapproval phase within the trial portfolio. Predictors of cause-specific rehospitalization were analyzed.

Results: The rates of rehospitalization were lower with HM3 LVAD than with HMII LVAD in the pivotal trial (225.7 vs 246.4 events per 100 patient-years; P < 0.05). Overall, rehospitalization rates and duration were similar in the HM3 postapproval phase and pivotal trial but prolonged hospitalizations (>7 days) were less frequent (rate ratio: 0.90 [95% CI: 0.80-0.98]; P < 0.05). In HM3 recipients, the most frequent causes of rehospitalization included infection, heart failure (HF)-related events, and bleeding. First rehospitalization caused by HF-related event versus other causes was associated with reduced survival (HR: 2.2 [95% CI: 1.3-3.9]; P = 0.0014). Male sex, non-White race, presence of cardiac resynchronization therapy/implantable cardioverter-defibrillator, obesity, higher right atrial pressure, smaller LV size, longer duration of index hospitalization, and lower estimated glomerular filtration rate at index discharge predicted HF hospitalizations.

Conclusions: Contemporary support with the HM3 fully magnetically levitated LVAD is associated with a lower hospitalization burden than with prior pumps; however, rehospitalizations for infection, HF, and bleeding remain important challenges for progress in the patient journey. (MOMENTUM 3 IDE Clinical Study, NCT02224755; MOMENTUM 3 Continued Access Protocol [MOMENTUM 3 CAP], NCT02892955).

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.jchf.2022.03.007	DOI Listing

July 2022

Publication Analysis

Top Keywords

magnetically levitated

Keyword Occurance

Similar Publications

Remote ischaemic conditioning in necrotising enterocolitis: a phase I feasibility and safety study.

Authors:

Carlos Zozaya Niloofar Ganji Bo Li Maarten Janssen Lok Carol Lee Yuhki Koike Estelle Gauda Martin Offringa Simon Eaton Prakeshkumar S Shah Agostino Pierro

Arch Dis Child Fetal Neonatal Ed 2022 Aug 8. Epub 2022 Aug 8.

Translational Medicine, Hospital for Sick Children Research Institute, University of Toronto, Toronto, Ontario, Canada

Objective: Remote ischaemic conditioning (RIC) improves the outcome of experimental necrotising enterocolitis (NEC) by preserving intestinal microcirculation. The feasibility and safety of RIC in preterm infants with NEC are unknown. The study aimed to assess the feasibility and safety of RIC in preterm infants with suspected or confirmed NEC. Read More

View Article and Full-Text PDF

August 2022

Similar Publications

KRAS-targeted therapy in the treatment of non-small cell lung cancer.

Authors:

Jina Yun Reid Nakagawa Kenneth Tham

J Oncol Pharm Pract 2022 Aug 8:10781552221118848. Epub 2022 Aug 8.

Pharmacy, 7284University of Washington/Fred Hutchinson Cancer Center, Seattle, USA.

Objective: mutations are one of the most common driver mutations in non-small cell lung cancer. Though previously believed to be an undruggable target, recent advances in therapeutics have seen new targeted agents against mutations. The objective of this article is to review currently available and upcoming KRAS-targeted treatments. Read More

View Article and Full-Text PDF

August 2022

Similar Publications

Benefits and Risks of a Staged-Bilateral VIM Versus Unilateral VIM DBS for Essential Tremor.

Authors:

Prarthana Prakash Guenther Deuschl Sarah Ozinga Kyle T Mitchell Binith Cheeran Paul S Larson Aristide Merola Sergiu Groppa Tucker Tomlinson Jill L Ostrem

Mov Disord Clin Pract 2022 Aug 14;9(6):775-784. Epub 2022 Jun 14.

Department of Neurology, UCSF Weill Institute for Neurosciences, Movement Disorder and Neuromodulation Center University of California San Francisco CA USA.

Background: Despite over 30 years of clinical experience, high-quality studies on the efficacy of bilateral versus unilateral deep brain stimulation (DBS) of the ventral intermediate (VIM) nucleus of the thalamus for medically refractory essential tremor (ET) remain limited.

Objectives: To compare benefits and risks of bilateral versus unilateral VIM DBS using the largest ET DBS clinical trial dataset available to date.

Methods: Participants from the US St. Read More

View Article and Full-Text PDF

August 2022

Similar Publications

Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial.

Authors:

Nina Shah Michel Delforge Jesus San-Miguel Olga Moshkovich Julia Braverman Devender S Dhanda Sally Lanar Matthew Miera Agnes Williams Ryan Murphy Jennifer Devlen Kristen Hege Timothy B Campbell Nikhil C Munshi

Leuk Res 2022 Jul 21;120:106921. Epub 2022 Jul 21.

The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Objective: To understand the experience of patients with relapsed and refractory multiple myeloma (RRMM) receiving idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in the pivotal, phase 2 KarMMa trial.

Methods: Optional semi-structured interviews before leukapheresis (pre-treatment) captured expectations and after ide-cel infusion (1, 2, and 3 months post-treatment), assessed treatment experience, ide-cel advantages/disadvantages, and health and well-being. In a mixed-method analysis, treatment experiences were categorized by clinical response status, health and well-being, and self-reported recovery after infusion. Read More

View Article and Full-Text PDF

July 2022

Similar Publications

Emerging drugs for the treatment of acne: a review of phase 2 & 3 trials.

Authors:

Siddharth Bhatt Rohit Kothari Durga Madhab Tripathy Sunmeet Sandhu Mahsa Babaei Mohamad Goldust

Expert Opin Emerg Drugs 2022 Aug 5. Epub 2022 Aug 5.

Department of Dermatology, University Medical Center Mainz, Mainz, Germany.

Introduction: Acne vulgaris is one of the commonest dermatoses encountered in a dermatology clinic. Although, the inflammatory processes are centered around the pilosebaceous unit, a myriad of external factors that alter the pathogenesis have been hypothesized. Newer therapies are focused on targeting these as possible scaffolds for drug development. Read More

View Article and Full-Text PDF

August 2022

Similar Publications

}

Search Our Scientific Publications & Authors